declined from 76% to 31% as a share of all uses from 1994 to 2007, while substantial increases in use occurred for bipolar affective disorder (5% to 39%) and depression (8% to 15%). The fraction of atypical antipsychotic use for indications with insufficient evidence of effi cacy increased from 32% in 1994 to 58% in 2007, representing 26 million prescriptions and $7.3 billion dollars in expenditures in 2007. During 2007, primary care physicians accounted for 21% of visits where an antipsychotic was used, as compared with psychiatrists (77%) or physicians from other specialties (2%). Antipsychotic use in settings of insuffi cient evidence was similar among primary care physicians and psychiatrists. CONCLUSIONS: The scope and costs of this expansion, due to both clinical innovation and overuse, demonstrate the importance of efforts to limit the clinical application of antipsychotics to settings of suffi cient evidence.
PMH10

RISK OF INJURY IN ADULTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER
Montejano LB 1 , Sasane R 2 , Hodgkins P 2 , Huse D 3 1 Thomson Reuters, Washington, DC, USA, 2 Shire Pharmaceuticals, Wayne, PA, USA, 3 Thomson Reuters, Cambridge, MA, USA OBJECTIVES: To evaluate the risk of injury associated with attention-defi cit hyperactivity disorder (ADHD) using information from an employee database. METHODS: Using the MarketScan Commercial Claims and Encounters Database from Thomson Reuters, patients aged 18 to 64 years and diagnosed with ADHD (N 31,752) were matched by similarity in demographics and data availability 3:1 to controls without ADHD (N 95,256) or 1:1 to controls diagnosed with depression (N 29,965). Patients with ADHD were also stratifi ed into compliant (Medication Possession Ratio [MPR] 0.8; N 8654), partially compliant (0.3 MPR 0.8; N 5233) and noncompliant (MPR 0.3; N 4007) cohorts. Risk of injury was compared between groups for January to December 2006. Multivariate analyses controlled for treatment differences between groups that remained after matching. RESULTS: Injury rates were higher in the ADHD group than in the non-ADHD control group (21.6% vs 15.7%, p 0.001) and depression group (21.4% vs. 20.5%, p 0.0085), and higher in the compliant group than in the partially compliant (22.8% vs 20.3, p 0.0004) and noncompliant (22.8% vs 17.8%, p 0.001) groups. In multivariate analyses, risk of injury was higher in the ADHD group than in the non-ADHD (1.3194 odds ratio [OR], p 0.01) and depression control groups (1.1263 OR, p 0.01) and higher in compliant and partially compliant patients than in noncompliant patients (1.2633 and 1.664 OR, respectively, p 0.01). Comorbid depression, anxiety and substance abuse predicted a higher risk of injury in the ADHD versus control groups (p 0.01) and in compliant/partially compliant patients versus noncompliant patients (p 0.01), with magnitude equal to or exceeding that of the ADHD group alone. CONCLUSIONS: Patients with ADHD had higher risk of injury than similarly matched patients without ADHD or with depression, suggesting important implications for workplace safety and liability.
PMH11 RISK ASSESSMENT OF POISONING WITH DRUGS OF THERAPEUTIC IMPORTANCE BY TOXICOVIGILANCE
Sam KG, Tunga G, Pandey S Manipal University, Manipal, Karnataka, India OBJECTIVES: Toxicovigilance studies were carried out with the aim to determine the health hazards, treatment and outcome of therapeutic drug overdose. METHODS: All therapeutic drug poisoned patients admitted to a tertiary care South Indian hospital. were evaluated for predisposing factors manner of exposure, severity at admission, treatment, hospitalization period, clinical status at discharge, , in order to implement medication safety programs. RESULTS: A total of 200 patients were admitted with therapeutic drug overdose. A total of 153 cases intentionally ingested the drugs, while 29 cases had overdose during routine therapy, and 18 cases had ingested the drugs accidentally. Depression was the major predisposing factor for intentional self harm. Most of the poisoning with therapeutic drugs occurred due to intentional self harm n 153 (76.5%). Other manner of exposures include overdose during therapeutic use n 29 (14.5%) or accidental exposure n 18 (9%). There was a signifi cant (P 0.001) association of employment and occupational status on the manner of exposure. The mean GCS, APACHE II scores, PMR and PSS for all the patients was 8.46 3.6; 20.63 5.0; 38.58 16.1 and 2.96 0.79 (Mean SD) respectively. The mean GCS score was signifi cantly (P 0.033) different between various class of poisoning. The APACHE II scores were not signifi cantly (P 0.05) different between various drug classes. The mean severity scores was signifi cantly (P 0.016) different between various class of drugs. The treatment provided was empirical and symptomatic with differing decontamination procedures. The average hospitalization period was 6.68 4.9 days with a median of 6 days range (3-8). Majority of them 189(94.5%) improved, while 5 patients were discharged with severe sequele, and six patients expired during hospital stay. CONCLUSIONS: The extent of harm caused due to therapeutic drug poisoning can be minimized by systematically estimating the severity at triage and providing treatment as per standardized guidelines.
PMH12 A META-ANALYSIS OF EFFICACY AND SAFETY OF PREGABALIN AND CLONAZEPAM IN THE TREATMENT OF ANXIETY DISORDERS
Villasis-Keever MA 1 , Rivas-Ruiz R 1 , Mould-Quevedo J Q J 2 1 Social Security Mexican Institute, Mexico City, Mexico, 2 Pfi zer Mexico, Mexico City, Mexico OBJECTIVES: The purpose of this study was to evaluate the relative effi cacy and safety of pregabalin and clonazepam in the treatment of anxiety disorders. METHODS: A meta-analysis was performed with randomized clinical trials (RCTs) where pregabalin or clonazepam were used for any anxiety disorders. Effectiveness was assessed with the Hamilton Anxiety Rating Scale (HAM-A); safety with the frequency and type of adverse events (AEs). RCT were searched in July 2008 in Medline, EMBASE, PsycInfo, CINAHL and the Cochrane Collaboration. Two independent reviewers identifi ed the abstracts, full articles, and then extracted data; results were compared and settled through consensus. RCT included both drugs and its comparison with placebo. Odds ratios and weighted means differences (WMD) were calculated. Both, fi xed and random effects models were employed in the analysis. RESULTS: From 1893 abstracts, we obtained 40 RCT, 23 were excluded (unacceptable designs, insuffi cient outcome data, no placebo control) leaving 17. Seven pregabalin studies were used to evaluate its effectiveness and safety; four clonazepam studies for effectiveness and six for safety. Clonazepam studies included panic disorder and social phobia. Six of seven pregabalin studies were in generalized anxiety disorder and one for social anxiety disorder. We found that both drugs signifi cantly diminished anxiety levels after four to 32 weeks of treatment. Among clonazepam studies the frequency of AEs was higher than placebo by nearly 50%; with pregabalin, less than 30%. We didn't found any headto-head studies with pregabalin and clonazepam and no statistical difference in anxiety level reduction was distinguished between drugs, WMD in HAM-A: 1.2(CI95% 1.13, 3.54). However, clonazepam showed higher AE rates than pregabalin in somnolence (OR 0.54; 95%CI 0.44-0.66), headache (OR 0.50; 0.34-0.74), blurred vision (OR 0.36; 0.13-0.98) and cognitive impairment (OR 0.25; 0.09-0.72). CONCLUSIONS: Clonazepam and pregabalin are effective in diminishing anxiety levels in several anxiety disorders, although clonazepam seems to cause a higher frequency of AEs.
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PMH14 BUDGETARY IMPACT OF WELL DIRECTED USE OF PALIPERIDONE ER IN GERMANY
Sindern J J 1 , Mehnert A 2 , Schroeder-Bernhardi D 3 1 Janssen-Cilag GmbH, Neuss, Germany, 2 Janssen-Cilag GmbH, Neuss, NRW, Germany, 2 3 IMS Health GmbH & Co. OHG, Frankfurt/Main, Hessen, Germany OBJECTIVES: Purpose of this analysis was to quantify the subgroup of schizophrenia patients with potential treatment benefi ts associated with the oral atypical antipsychotic Paliperidone ER (PER) according to its clinical profi le (limited liability for hepatic drug-drug interactions (DDI) via CYP450) and to assess the budgetary impact of targeted use of PER for treatment of these patients. METHODS: In a retrospective study of longitudinal patient data from Germany using IMS Disease Analyzer, medical records from patients with at least one diagnosis of schizophrenia (ICD10 F20-F29) between July 2007 and June 2008 were analyzed. For the last quarter of the study period prescriptions of antipsychotic and concomitant medication of schizophrenia
